Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425306 · ClinicalTrials.gov registry record · Phase 1
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
A Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02425306 is a Phase 1 study that was terminated before completion, run by Craig L Slingluff, Jr. The registered enrollment target is 48 participants.
The verdict
NCT02425306, a Phase 1 study, was terminated before completion, sponsored by Craig L Slingluff, Jr.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study evaluates whether it is safe to administer a peptide vaccine in combination with different adjuvants. Adjuvants are substances that may boost immune responses vaccines. In this study, the adjuvants are Montanide ISA-51, polyICLC and cyclophosphamide. This study will also evaluate the effects of the combination of the peptide vaccine and the adjuvants on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tissue from the sites of vaccination.
Interventions
- DRUG Cyclophosphamide
- DRUG Montanide ISA-51
- BIOLOGICAL 6MHP
- DRUG polyICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-05-12 |
| Est. Completion | 2018-01-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02425306
The ClinicalTrials.gov registry entry for NCT02425306 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02425306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02425306 about?
NCT02425306 is a clinical study titled "Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma". This study evaluates whether it is safe to administer a peptide vaccine in combination with different adjuvants. Adjuvants are substances that may boost immune responses vaccines. In this study, the adjuvants are Montanide ISA-51, polyICLC and cyclophosphamide. This study will also evaluate the effe...
What is the current status of trial NCT02425306?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2015-05-12. Estimated completion is 2018-01-08.
What interventions are being tested in trial NCT02425306?
The interventions under investigation include: Cyclophosphamide (DRUG), Montanide ISA-51 (DRUG), 6MHP (BIOLOGICAL), polyICLC (DRUG).
Who is sponsoring clinical trial NCT02425306?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.